MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Personalis, Inc.

< Previous 1 2 3 4 Next >
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis and Tempus Announce Expanded Collaboration
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Second Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce Second Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
From Personalis, Inc.
Via Business Wire
Tickers PSNL
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports First Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce First Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Third Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story